e-therapeutics_primary_logo.png
e-therapeutics Announces Business Updates and Interim Results
October 31, 2024 09:00 ET | e-therapeutics plc
LONDON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced business...
Recursion updates L(
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
August 08, 2024 01:32 ET | Recursion Pharmaceuticals
Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates...
Recursion to Report
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
August 05, 2024 16:01 ET | Recursion Pharmaceuticals
Salt Lake City, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide...
Recursion to Partici
Recursion to Participate in Upcoming Investor Conferences
June 03, 2024 09:00 ET | Recursion Pharmaceuticals
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
image1 (1).png
Evaxion Announces Business Update and First Quarter 2024 Financial Results
May 28, 2024 08:21 ET | Evaxion Biotech
COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™...
Recursion to Partici
Recursion to Participate in Upcoming Investor Conferences
May 01, 2024 08:01 ET | Recursion Pharmaceuticals
SALT LAKE CITY, May 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Recursion to Partici
Recursion to Participate in Upcoming Investor Conference
April 02, 2024 08:00 ET | Recursion Pharmaceuticals
SALT LAKE CITY, April 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
image1 (1).png
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
March 19, 2024 07:30 ET | Evaxion Biotech
The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI and machine learning technologiesAI-Immunology™ outcompetes...
Recursion to Partici
Recursion to Participate in Upcoming Investor Conferences
March 01, 2024 07:59 ET | Recursion Pharmaceuticals
SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
logo2 (1).png
IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine
January 24, 2024 03:00 ET | IMU Biosciences
Board strengthened with appointments of Tim Haines (Abingworth) as Non-executive Chair and Dr Oliver Nussbaumer (co-founder of GammaDelta Therapeutics and Adaptate Biotherapeutics) and Dr Inga Deakin...